AKT1 and cancer: The PI3K/AKT/mTOR pathway: Previous studies have demonstrated that this pathway can modulate proliferation and angiogenesis in endometriosis [135], and that two rapamycin-analogues (temsirolimus and everolimus), already used in various cancers, inhibit mTOR signaling and reduce the growth of endometriosis implants [136].